These final results, along with a past report demonstrating that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like actions in mice,two support the strategy of focusing on ACKR3 as a unique approach to modulate the opioid program, which could open new therapeutic avenues for opioid-connected Ailments.Distributing this review means that